

30 November 2023

ASX Code: MXC

LSE Code: MXC

Results of Shareholder's Annual General Meeting

A
S
X

R
E
L
E
A
S
E

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') would like to announce the results from the Company's Annual General Meeting of Shareholders held today, Thursday, 30 November 2023, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried.

Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached report.

—Ends—

Authorised for release by the Company Secretary, for further information please contact:

MGC Pharmaceuticals Ltd

Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@mgcpharma.co.uk

UK IR/PR Advisers

IFC Advisory

Graham Herring / Tim Metcalfe / Zach Cohen
+44 203 934 6630
mgcpharma@investor-focus.co.uk

MGC Pharmaceuticals Ltd

Rowan Harland
Company Secretary
+61 8 6555 2950
info@mgcpharma.co.uk

UK Brokers

Oberon Capital

Aimee McCusker / Adam Pollock
+44 203 179 5300
aimeemccusker@oberoninvestments.com
adampollock@oberoninvestments.com

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a prominent European pharmaceutical company with a strong commitment to creating accessible and ethically produced cutting-edge medicines. Our approach combines in-house research with innovative technologies, all aimed at discovering and producing treatments for currently unmet medical conditions.

The company's founders and executives are distinguished figures in the global pharmaceutical industry. Our central business strategy revolves around the development and supply of innovative medicines, responding to the increasing demand in the medical markets of Europe, North America, and Australasia.

MGC Pharma maintains a robust development pipeline that addresses two prevalent medical conditions, with additional products currently in the developmental stages. We've established strategic partnerships with renowned institutions and academia, fostering the optimization of our medicines' development. These medicines are produced in our EU-GMP Certified manufacturing facilities, ensuring the highest quality standards.

With a growing patient base in key regions like the USA, UK, Australia, and Ireland, MGC Pharma has also built a global distribution network through a wide-reaching group of commercial partners. This extensive network places us in a prime position to supply the global market effectively.

Follow us through our social media channels:

LinkedIn: MGC Pharmaceuticals Ltd.

Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

Instagram: @mgc_pharma

info@mgcpharma.co.uk | mgcpharma.co.uk

MGC Pharmaceuticals Ltd | Suite 1, 295 Rokeby Road, Subiaco WA 6008

T: +61 8 6555 2950

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	14,933,355 99.56%	55,245 0.37%	10,978 0.07%	1,478	14,944,876 99.63%	55,245 0.37%	1,478	Carried
2 Election of Director - Layton Mills	Ordinary	14,983,974 99.89%	12,082 0.08%	4,636 0.03%	364	14,989,153 99.92%	12,082 0.08%	364	Carried
3 Re-election of Director - Stephen Parker	Ordinary	14,983,523 99.90%	11,175 0.07%	4,821 0.03%	1,537	14,988,887 99.93%	11,175 0.07%	1,537	Carried
4 Approval of 7.1A Mandate	Special	14,929,577 99.60%	56,068 0.37%	4,955 0.03%	10,456	14,934,540 99.62%	56,603 0.38%	10,456	Carried
5 Confirmation of Appointment of Auditor	Ordinary	14,951,116 99.68%	43,284 0.29%	4,955 0.03%	1,701	14,956,614 99.71%	43,284 0.29%	1,701	Carried
6 Ratification of Prior Issue of Tranche 1 Placement Options	Ordinary	14,937,149 99.61%	53,848 0.36%	4,636 0.03%	5,423	14,942,328 99.64%	53,848 0.36%	5,423	Carried
7 Approval to Issue Tranche 2 Placement Options	Ordinary	14,934,778 99.60%	56,119 0.37%	4,754 0.03%	5,405	14,939,540 99.62%	56,654 0.38%	5,405	Carried
8 Approval to Issue Shares and Options to Mercer	Ordinary	14,928,721 99.55%	63,699 0.42%	4,636 0.03%	4,000	14,933,900 99.58%	63,699 0.42%	4,000	Carried

9 Approval to Increase Maximum Securities under the Company's Employee Securities Incentive Plan	Ordinary	14,927,462	60,105	4,636	8,853	14,932,106	60,640	8,853	Carried
		99.57%	0.40%	0.03%		99.60%	0.40%		

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.